IMV INC.
IMV
 Delayed - 01/26 11:06:34 am |
|
| 4.34CAD | -4.62% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Biotechnology & Medical Research | |||
| Biotechnology & Medical Research | |||
| Biotechnology & Medical Research - Other | |||
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.
Sales per Business
| 2018 | 2019 | |||
| CAD (in Million) | % | CAD (in Million) | % | |
| Immunotherapies | 0.082 | 100% | 0.059 | 100% |
Sales per region
| 2018 | 2019 | |||
| CAD (in Million) | % | CAD (in Million) | % | |
| Canada | 0.082 | 100% | 0.059 | 100% |
Managers
| Name | Title |
| Frederic Ors | Chief Executive Officer & Non-Independent Director |
| Andrew J. Sheldon | Chairman |
| Ryan Marshall | Vice President-Project Management & Operations |
| Pierre Labbé | Chief Financial Officer |
| Marianne Stanford | Vice President-Research & Development |
| Joanne Schindler | Chief Medical Officer |
| James Willis Hall | Independent Director |
| Wayne F. Pisano | Independent Director |
| Shermaine Tilley | Independent Director |
| Julia Paige Gregory | Independent Director |
| Shareholders |
| Name | Equities | % |
| Ruffer LLP | 7,453,399 | 11.1% |
| Fonds de Solidarité FTQ | 5,111,533 | 7.62% |
| VHCP Management LLC | 3,150,000 | 4.69% |
| Albert Scardino | 2,362,974 | 3.52% |
| Fidelity (Canada) Asset Management ULC | 800,000 | 1.19% |
| Fidelity Investments Canada ULC | 710,000 | 1.06% |
| Wells Fargo Clearing Services LLC | 355,038 | 0.53% |
| Ghost Tree Capital LLC | 325,000 | 0.48% |
| Frederic Ors | 284,907 | 0.42% |
| Intact Investment Management, Inc. | 242,418 | 0.36% |
Company contact information
IMV, Inc.
130 Eileen Stubbs Avenue
Suite 19
Dartmouth, NS B3B 2C4
Phone : +1.902.492.1819
Fax : +1.902.492.0888
Web : http://www.imv-inc.com
130 Eileen Stubbs Avenue
Suite 19
Dartmouth, NS B3B 2C4
Phone : +1.902.492.1819
Fax : +1.902.492.0888
Web : http://www.imv-inc.com
Sector Biotechnology & Medical Research - Other
| 1st jan. | Capi. (M$) | ||
 | |||
| IMV INC. | 16.97% | 247 | |
| |||
| MODERNA, INC. | 40.71% | 58 169 | |
| LONZA GROUP AG | 6.79% | 50 766 | |
| CELLTRION, INC. | -10.58% | 39 697 | |
| IQVIA HOLDINGS INC. | 2.15% | 35 090 | |
| SEAGEN INC. | 2.84% | 32 583 | |
| HANGZHOU TIGERMED CONSULTING CO.,LTD | 18.50% | 25 245 | |
| INCYTE CORPORATION | 12.54% | 22 009 | |
| ALNYLAM PHARMACEUTICALS, INC. | 35.18% | 20 412 | |
| PHARMARON BEIJING CO., LTD. | 40.91% | 20 367 | |
| BIO-TECHNE CORPORATION | 10.99% | 13 607 | |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 12.13% | 13 607 | |
| CRISPR THERAPEUTICS AG | 18.37% | 13 396 | |
| QIAGEN N.V. | 1.89% | 12 246 | |
| PPD, INC. | 1.99% | 12 203 | |
| ICON PUBLIC LIMITED COMPANY | 10.07% | 11 326 | |
| IONIS PHARMACEUTICALS, INC. | 12.81% | 8 918 | |
| ACADIA PHARMACEUTICALS INC. | 0.92% | 8 577 | |
| PRA HEALTH SCIENCES, INC. | 4.74% | 8 428 | |
| SYNEOS HEALTH, INC. | 14.27% | 8 090 | |
| UNITED THERAPEUTICS CORPORATION | 11.57% | 7 526 | |
